Oragenics, Inc. Files 10K and Provides Company Update
April 01 2024 - 9:05AM
Business Wire
Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company
focused on developing unique, intranasal pharmaceuticals for the
treatment of neurological disorders, today announced that it has
filed its annual report on March 29, 2024. The Company is pleased
to report it has executed on its strategy to diversify its product
development portfolio and makes progress in transforming the
Company to create long term value. Some key items that have helped
to improve the Company moving forward are:
- The Company acquired a platform technology intended to treat
multiple neurological disorders. The first target indication is for
concussion and the technology has successfully completed a Phase I
trial.
- Raised approximately $ 2.1 million in a public offering and
$890,000 in a private transaction.
- Hired a Chief Medical Officer: Dr James Kelly MD, is a thought
leader in brain injury including concussion.
- Added two new Board members: John Gandolfo and Bruce
Cassidy.
- Created a subsidiary in Australia to take advantage of R&D
rebates offered by the Australian government.
- Contracted with a leading Contract Research Organization to
oversee our Phase II clinical trial.
- Manufacturing drug in preparation for our Phase II trial.
We are excited about the progress the Company has made in the
past several months. We are creating a team with the experience and
drive to further our neurological drug candidates through clinical
trials during 2024,” commented Michael Redmond, President of
Oragenics.
As previously disclosed in its Annual Report on Form 10-K for
the year ended December 31, 2023, which was filed on March 29, 2024
with the Securities and Exchange Commission, the audited
consolidated financial statements contained an unqualified audit
opinion from its independent registered public accounting firm that
included an explanatory paragraph related to the Company’s ability
to continue as a going concern. See further discussion in footnote
1 of the Company’s consolidated financial statements included in
the Company’s Annual Report on Form 10-K.
About Oragenics
Oragenics is a development-stage biotechnology company focused
on nasal delivery of pharmaceutical medications in neurology and
fighting infectious diseases, including drug candidates for
treating mild traumatic brain injury (mTBI), also known as
concussion, and for treating Niemann Pick Disease Type C (NPC), as
well as proprietary powder formulation and an intranasal delivery
device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those described in our Form 10-K and other filings
with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You
should consider these factors in evaluating the forward-looking
statements included in this press release and not place undue
reliance on such statements. We do not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328369604/en/
Oragenics, Inc. Janet Huffman, Chief Financial Officer
813-286-7900 jhuffman@oragenics.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024